In the final analysis of the phase 1/2 study, brigatinib was found to have sustained long-term activity and PFS in patients with ALK+ NSCLC at a median follow-up of 27.7 months (range: 0.2–88.3) and more than 5 years after the last patient was enrolled. The gene discussed is ALK; the disease is non-small cell lung carcinoma.